In order to respond to the rising prevalence of chronic diseases worldwide, it has been necessary for the bio/pharmaceutical industry to innovate across the whole development lifecycle — from discovery through to formulation and manufacturing...

Chronic respiratory disorders, such as chronic obstructive pulmonary disease, asthma, allergic rhinitis, and sinusitis, are becoming increasingly prevalent and considered to be “major contributors to the growing global burden of non-communicable diseases.”…

Various global and market-specific trends are transforming the bio/pharmaceutical industry, leading to the need for new strategies and investment across the full value chain...

The latest edition of CPHI Frankfurt wrapped on Thursday Oct. 30, 2025 after welcoming approximately 62,000 visitors from over 166 countries, making it the largest ever CPHI event. Over 2,500 exhibitors attended the 36th iteration, a vast increase from the event’s humble beginnings back in 1990 when there were only 16 exhibitors…

Given the sheer size of the event, which is growing exponentially year-over-year, a huge amount of planning is required and there are a lot of event happenings that should not be missed, specifies Tara Dougal, Event Director — Pharma at Informa Markets…

An increasingly complex therapeutic development pipeline, global market shifts, a drive for greater cost efficiency, and a need to employ more advanced technologies are some of the key factors leading bio/pharma companies of all sizes to adjust their operational strategies...

The global bio/pharmaceutical industry is facing a crossroads: while therapeutic innovation continues at a rapid pace, the return on investment from such innovation is proving to be less pleasing for company shareholders...

To successfully develop and market a drug product, bio/pharmaceutical companies must adhere to strict regulations and guidelines, which have been set out to ensure quality, efficacy, and safety standards are met...

Pharmaceutical packaging solution providers need to consider a host of factors when developing potential solutions for the costly drug products to be housed within. Not only must packaging be secure and practical, but it must also account for the increasing need for greater flexibility and improved user convenience…

The global biopharmaceutical industry has been experiencing a period of significant growth over recent years, with biologic-based drugs comprising an expanding share of the market...

Biologic-based therapeutics are increasingly in demand, thanks to their ability to provide more targeted and personalized treatment options for a variety of chronic and difficult-to-treat conditions…

Formulating a drug product is one of the most important parts of development and can determine whether or not a company will be triumphant when they seek commercialization...

Oral delivery is still the preferred route of administration for most approved, commercially available products. Thanks to the popularity of the dosage form, demand for oral solid drugs, or OSDs, continues to rise, and market research anticipates that there will be further innovations in the field to help overcome the challenges associated with the rising complexity of APIs…

So far, 2025 has been financially challenging for the biopharmaceutical and biotech sectors — with limited access to capital and lean financing on offer — further complicated by macroeconomic uncertainty…

Marking a highlight of the year for the biotechnology industry, the BIO International Convention will convene once again in Boston, Mass., and is set to offer visitors four days of networking events and expert-driven sessions…

Novel therapeutic modalities, such as cell, gene, and nucleic acid therapies, are offering more effective, personalized treatment options to patients with chronic and/or rare diseases that were, not too long ago, considered to be untreatable…

CPHI Americas has wrapped for 2025, closing its doors at noon (EST) on May 22 after having welcomed over 3,925 attendees and 370 exhibitors, as well as 16 start-ups and 82 speakers…

As the month of May marches on, the city of Philadelphia prepares itself to once again play host to CPHI — this year under its new guise of CPHI Americas. For 2025, the event organizers have updated the name of the show to reflect the broader audience, which incorporates Latin America and Canada in addition to North America…

Glucagon-like peptide-1 (GLP-1) receptor agonists first penetrated the market 20 years ago when exenatide (Byetta, originally developed by Amylin Pharmaceuticals and Eli Lilly) gained regulatory approval as a novel treatment option for type 2 diabetes…

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization…